* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

NicOx

Nicox Q1 earnings drop on base effect, naproxinod expenses; has sufficient cash

finanznachrichten.de
May 14, 2008
        

PARIS (Thomson Financial) - French pharmaceutical group Nicox swung to a net loss of 12.96 million euros in the first quarter of 2008 from a profit of 1.80 million a year earlier reflecting higher operating expenses and the non-recurrence of one-off payments. It said the increase in operating...

add comment
                   

Paris shares close flat, off lows; Credit Agricole drags banks lower UPDATE

finanznachrichten.de
May 13, 2008 59 related
        

PARIS (Thomson Financial) - Share prices closed flat, partly reversing this morning's losses, but bank stocks remained mostly negative as Credit Agricole's surprise announcement of a 5.9 billion euro capital increase rekindled fears about the sector. The CAC-40 index finished up 22.46 points or...

add comment
                   

NicOx Announces U.S. Phase 2a Results For PF-03187207 And Gives An Update On Continuing...

medicalnewstoday.com
May 7, 2008 12 related
        

NicOx S.A. (Euronext Paris: COX) announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan(R) (latanoprost) 0.005% in patients with primary open-angle glaucoma and ocular hypertension.

add comment

COPD And Asthma - Proprietary FANA™ Chemistry Platform For RNA-Silencing Therapeutics Described

medicalnewstoday.com
May 5, 2008
        

TOPIGEN Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, described progress of its proprietary FANA™ oligonucleotide chemistry platform at the RNAi World Congress on April 30, 2008, Boston, MA. Nicolay Ferrari, Ph.D.

add comment

NicOx signs agreement for commercial manufacture of Naproxcinod drug substance

news-medical.net
Mar 21, 2008 9 related
        

NicOx S.A. (Euronext Paris: COX) has announced it has signed an agreement with the fine chemical company Archimica, for the commercial manufacturing and supply of naproxcinod drug substance (or active pharmaceutical ingredient, API). ... Michele Garufi, Chairman and CEO...

add comment

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As...

redorbit.com
Mar 21, 2008 4 related
        

NEW YORK, March 20 /PRNewswire/ -- QED International Associates Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced the quarterly rebalancing of the Indexes.

add comment

Nicox signs agreement with Archimica for manufacture of naproxcinod drug

finanznachrichten.de
Mar 19, 2008
        

PARIS (Thomson Financial) - Nicox said it has signed an agreement with Archimica for the commercial manufacture and supply of its naproxcinod drug, which ... ... PARIS (Thomson Financial) - Nicox said it has signed an agreement with Archimica for the commercial...

add comment

NicOx Initiates Two Large ABPM Studies For Naproxcinod In Hypertensive Patients With Osteoarthritis

medicalnewstoday.com
Mar 4, 2008 17 related
        

NicOx S.A. (Euronext Paris: COX) announced the initiation of two large clinical pharmacology studies in the United States, which will assess the blood pressure profile of naproxcinod in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring (ABPM) technique.

add comment

Notice of Annual General Meeting in Orexo AB (Business Wire)

yahoo.com
Mar 4, 2008 8 related
        

UPPSALA, Sweden----Regulatory News: ... UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: The shareholders in Orexo AB (publ)(STO:ORX), Reg. No. 556500-0600, are hereby summoned to the annual general meeting (the “Meeting”), to be held on Thursday 3 April 2007, at 5.00...

add comment

Paris shares TFN market data at 10.45 am; shares track Wall St higher

finanznachrichten.de
Feb 26, 2008 33 related
        

PARIS (Thomson Financial) - Market data at 10.45 am: Major indices: CAC-40 up 54.33 points or 1.10 pct at 4,973.59 SBF-80 up 80.62 or 1.42 pct at 5,747.49 ... ... PARIS (Thomson Financial) - Market data at 10.45 am: 38 CAC-40 stocks up 2 CAC-40 stocks down Major gainers:...

add comment